The Use of a Novel Biomarker for the Rapid and Accurate Diagnosis of Septic Effusions in Dogs

Area of Study: 
Internal Medicine

Purpose of Study: 

Septic cavitary effusions are life-threatening conditions with reported mortality rates of up to 56% in dogs.

Early recognition and prompt institution of appropriate therapy is crucial in ensuring the best outcome. 

A growing body of data in human and veterinary patients suggests that neutrophil gelatinase-associated lipocalin (NGAL) is a sensitive marker of bacterial infections.

We propose investigating NGAL’s performance in distinguishing septic from non-septic effusions in dogs.

We aim to identify significant differences in NGAL values will then be used as preliminary data for continued collaboration

between clinical faculty and basic science researchers at ISU to develop a reliable point-of-care NGAL assay for use in dogs

and other veterinary species with a goal of improving antimicrobial stewardship in veterinary medicine.


Dogs with cavity effusion that identified as:

septic effusion

non-infectious inflammatory

cardiogenic effusion

low-oncotic pressure effusion

malignant effusion

Client Responsibilities: 

If you agree to have your animal participate in this study, while your pet visits the Lloyd Veterinary Medical Center,

we will collect effusion samples and blood from your pet. 

Client Benefits: 

There is no cost to you for your animal's participation in this study.

You will be responsible for any costs associated with the normal course of treatment, the treatment of any complications that may arise, and unrelated medical conditions.

You will not be compensated for your animal’s participation in this study.

We genuinely appreciate your dedication in helping future veterinary medicine.


You are encouraged to ask questions at any time during this study. 

For further information about the study, contact Dr. Jean-Sebastien Palerme, at 515-294-4900